Xenon Pharmaceuticals Inc. XENE
We take great care to ensure that the data presented and summarized in this overview for Xenon Pharmaceuticals Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding XENE
View all-
Avoro Capital Advisors LLC New York, NY5.4MShares$196 Million3.08% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.34MShares$157 Million1.31% of portfolio
-
Braidwell LP Stamford, CT3.61MShares$131 Million6.91% of portfolio
-
Janus Henderson Group PLC London, X03.58MShares$130 Million0.06% of portfolio
-
Capital International Investors Los Angeles, CA3.18MShares$115 Million0.02% of portfolio
-
Commodore Capital LP New York, NY3.03MShares$110 Million8.83% of portfolio
-
Polar Capital Holdings PLC London, X02.7MShares$97.9 Million0.49% of portfolio
-
Wellington Management Group LLP Boston, MA2.17MShares$78.7 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.1MShares$75.9 Million0.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V82.03MShares$73.6 Million0.09% of portfolio
Latest Institutional Activity in XENE
Top Purchases
Top Sells
About XENE
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Insider Transactions at XENE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 05
2025
|
Steven Gannon |
SELL
Open market or private sale
|
Direct |
3
-0.04%
|
$90
$30.48 P/Share
|
|
May 14
2025
|
Steven Gannon |
BUY
Exercise of conversion of derivative security
|
Direct |
5,144
+41.86%
|
$61,728
$12.57 P/Share
|
|
Jan 27
2025
|
Ian Mortimer PRESIDENT & CEO |
SELL
Open market or private sale
|
Direct |
16,315
-18.09%
|
$652,600
$40.76 P/Share
|
|
Jan 27
2025
|
Ian Mortimer PRESIDENT & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,315
+14.01%
|
$277,355
$17.76 P/Share
|
|
Jan 24
2025
|
Ian Mortimer PRESIDENT & CEO |
SELL
Open market or private sale
|
Direct |
22,468
-41.79%
|
$898,720
$40.2 P/Share
|
|
Jan 24
2025
|
Ian Mortimer PRESIDENT & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,468
+29.47%
|
$381,956
$17.76 P/Share
|
|
Jan 23
2025
|
Ian Mortimer PRESIDENT & CEO |
SELL
Open market or private sale
|
Direct |
16,217
-34.13%
|
$648,680
$40.08 P/Share
|
|
Jan 23
2025
|
Ian Mortimer PRESIDENT & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,217
+25.44%
|
$275,689
$17.76 P/Share
|
|
Dec 18
2024
|
Sherry Aulin Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
18,709
-100.0%
|
$767,069
$41.21 P/Share
|
|
Dec 18
2024
|
Sherry Aulin Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,625
-25.47%
|
$271,625
$41.28 P/Share
|
|
Dec 18
2024
|
Sherry Aulin Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,334
+50.0%
|
$253,340
$10.51 P/Share
|
|
Nov 22
2024
|
Gary Patou |
SELL
Open market or private sale
|
Direct |
4,891
-9.38%
|
$200,531
$41.08 P/Share
|
|
Nov 22
2024
|
Gary Patou |
SELL
Payment of exercise price or tax liability
|
Direct |
1,695
-3.16%
|
$66,105
$39.8 P/Share
|
|
Nov 22
2024
|
Gary Patou |
BUY
Exercise of conversion of derivative security
|
Direct |
6,586
+10.91%
|
$65,860
$10.43 P/Share
|
|
Mar 08
2024
|
Elizabeth A. Garofalo |
SELL
Open market or private sale
|
Direct |
2,092
-100.0%
|
$94,140
$45.69 P/Share
|
|
Mar 08
2024
|
Elizabeth A. Garofalo |
SELL
Payment of exercise price or tax liability
|
Direct |
1,408
-40.23%
|
$64,768
$46.16 P/Share
|
|
Mar 08
2024
|
Elizabeth A. Garofalo |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+50.0%
|
$63,000
$18.56 P/Share
|
|
Mar 07
2024
|
Sherrington Robin EVP, Strategy & Innovation |
SELL
Open market or private sale
|
Direct |
7,137
-24.35%
|
$328,302
$46.23 P/Share
|
|
Mar 07
2024
|
Sherrington Robin EVP, Strategy & Innovation |
SELL
Payment of exercise price or tax liability
|
Direct |
1,504
-4.95%
|
$67,680
$45.96 P/Share
|
|
Mar 07
2024
|
Sherrington Robin EVP, Strategy & Innovation |
BUY
Exercise of conversion of derivative security
|
Direct |
8,641
+20.96%
|
$77,769
$9.85 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 92.1K shares |
|---|
| Open market or private sale | 78.6K shares |
|---|---|
| Payment of exercise price or tax liability | 8.32K shares |